This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.
That combination has made prostate cancer an enticing target for drug developers and in particular those working on cancer immunotherapies, but both PD-1 and PD-L1 checkpoint inhibitors have largely ... The company thinks its phase 3 programme is the
Its ‘memory cancer vaccine’ consists of a cocktail of off-the-shelf NK cells delivered alongside low-dose chemotherapy, cytokines, yeast- and adenovirus-delivered tumour antigens and PD-1/PD-L1 ... checkpoint inhibitors – all designed to stimulate
Taken together, while checkpoint inhibitors are now the standard of care in frontline RCC, PD-L1-positive patients tend to derive the most benefit,” notes Hsieh. ... In our view, combination with TKI could expand the clinical benefit of checkpoint
Firm aims to leapfrog immunotherapy leaders in huge market. The PD-1/PD-L1 category has been transforming cancer treatment in Western markets, but so far just one of the five ... There is a huge pent-up need for new cancer immunotherapies. However, while
Armo has said it thinks that the drug will increase the activity of PD-1/PD-L1 checkpoint inhibitors. ... Lilly already has a PD-L1 drug in phase I testing, while Armo also has a PD-1 antibody heading for clinical trials as well as recombinant IL-12 and
Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will also not go ahead. ... 1/PD-L1 inhibitors, but the drug has been firmly relegated to speculative status.
More from news
Approximately 1 fully matching, plus 31 partially matching documents found.
In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing
Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.
is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.
PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...